Now showing items 1-8 of 8

    • Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. 

      Pettitt, SJ; Krastev, DB; Brandsma, I; Dréan, A; Song, F; Aleksandrov, R; Harrell, MI; Menon, M; Brough, R; Campbell, J; Frankum, J; Ranes, M; Pemberton, HN; Rafiq, R; Fenwick, K; Swain, A; Guettler, S; Lee, J-M; Swisher, EM; Stoynov, S; Yusa, K; Ashworth, A; Lord, CJ (2018-05-10)
      Although PARP inhibitors (PARPi) target homologous recombination defective tumours, drug resistance frequently emerges, often via poorly understood mechanisms. Here, using genome-wide and high-density CRISPR-Cas9 ...
    • Identification of recurrent noncoding mutations in B-cell lymphoma using capture Hi-C. 

      Cornish, AJ; Hoang, PH; Dobbins, SE; Law, PJ; Chubb, D; Orlando, G; Houlston, RS (2019-01)
      The identification of driver mutations is fundamental to understanding oncogenesis. Although genes frequently mutated in B-cell lymphoma have been identified, the search for driver mutations has largely focused on the ...
    • Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. 

      Zhang, AW; McPherson, A; Milne, K; Kroeger, DR; Hamilton, PT; Miranda, A; Funnell, T; Little, N; de Souza, CPE; Laan, S; LeDoux, S; Cochrane, DR; Lim, JLP; Yang, W; Roth, A; Smith, MA; Ho, J; Tse, K; Zeng, T; Shlafman, I; Mayo, MR; Moore, R; Failmezger, H; Heindl, A; Wang, YK; Bashashati, A; Grewal, DS; Brown, SD; Lai, D; Wan, ANC; Nielsen, CB; Huebner, C; Tessier-Cloutier, B; Anglesio, MS; Bouchard-Côté, A; Yuan, Y; Wasserman, WW; Gilks, CB; Karnezis, AN; Aparicio, S; McAlpine, JN; Huntsman, DG; Holt, RA; Nelson, BH; Shah, SP (2018-06)
      High-grade serous ovarian cancer (HGSC) exhibits extensive malignant clonal diversity with widespread but non-random patterns of disease dissemination. We investigated whether local immune microenvironment factors shape ...
    • Measuring single cell divisions in human tissues from multi-region sequencing data. 

      Werner, B; Case, J; Williams, MJ; Chkhaidze, K; Temko, D; Fernández-Mateos, J; Cresswell, GD; Nichol, D; Cross, W; Spiteri, I; Huang, W; Tomlinson, IPM; Barnes, CP; Graham, TA; Sottoriva, A (2020-02-25)
      Both normal tissue development and cancer growth are driven by a branching process of cell division and mutation accumulation that leads to intra-tissue genetic heterogeneity. However, quantifying somatic evolution in ...
    • Mutational processes contributing to the development of multiple myeloma. 

      Hoang, PH; Cornish, AJ; Dobbins, SE; Kaiser, M; Houlston, RS (2019-08-06)
      To gain insight into multiple myeloma (MM) tumorigenesis, we analyzed the mutational signatures in 874 whole-exome and 850 whole-genome data from the CoMMpass Study. We identified that coding and non-coding regions are ...
    • RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. 

      Nava Rodrigues, D; Casiraghi, N; Romanel, A; Crespo, M; Miranda, S; Rescigno, P; Figueiredo, I; Riisnaes, R; Carreira, S; Sumanasuriya, S; Gasperini, P; Sharp, A; Mateo, J; Makay, A; McNair, C; Schiewer, M; Knudsen, K; Boysen, G; Demichelis, F; de Bono, JS (2019-01)
      PURPOSE:Metastatic castration-resistant prostate cancer (mCRPC) is a lethal but clinically heterogeneous disease, with patients having variable benefit from endocrine and cytotoxic treatments. Intrapatient genomic heterogeneity ...
    • A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products. 

      Ferrarini, A; Forcato, C; Buson, G; Tononi, P; Del Monaco, V; Terracciano, M; Bolognesi, C; Fontana, F; Medoro, G; Neves, R; Möhlendick, B; Rihawi, K; Ardizzoni, A; Sumanasuriya, S; Flohr, P; Lambros, M; de Bono, J; Stoecklein, NH; Manaresi, N (2018-01)
      Chromosomal instability and associated chromosomal aberrations are hallmarks of cancer and play a critical role in disease progression and development of resistance to drugs. Single-cell genome analysis has gained interest ...
    • Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms. 

      Hoang, PH; Dobbins, SE; Cornish, AJ; Chubb, D; Law, PJ; Kaiser, M; Houlston, RS (2018-11)
      Multiple myeloma (MM) is a biologically heterogeneous malignancy, however, the mechanisms underlying this complexity are incompletely understood. We report an analysis of the whole-genome sequencing of 765 MM patients from ...